# Xencor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xencor

- Industry: Biotechnology
- Headquarters: Monrovia, US
- Website: www.xencor.com
- Total disclosed funding: $68M
- Latest round: Series A (Jun 28, 2013)
- Investors on record: 7

## About

Xencor, Inc. is a biopharmaceutical company focused on developing innovative antibody therapeutics utilizing its proprietary XmAb® protein engineering platform to improve treatment outcomes in oncology and other serious diseases.Founded in 1997 in Monrovia, US, Xencor, Inc. engages in the development of antibody therapeutics. The company has undergone significant growth since its inception, raising a total of USD 70.00 mn during its IPO on December 3, 2013, by offering 12.7 million shares at USD 5.50 per share. The current CEO is Bassil Dahiyat, who has a strong background in the biopharmaceutical sector.Xencor specializes in the engineering of antibody therapeutics through its proprietary XmAb® protein engineering platform. The company's core product offerings include a portfolio of bispecific antibodies designed to engage multiple disease targets, thereby enhancing therapeutic efficacy and patient outcomes in oncology and other serious diseases. The XmAb-engineered Fc domains facilitate the development of highly selective immune modulators and targeted cancer therapies, which have shown potential in treating various malignancies. Xencor's drug candidates, including XmAb819 and XmAb808, are currently in various stages of clinical testing, with over 20 programs underway and several products marketed through strategic partnerships with pharmaceutical companies globally, notably in North America and Europe.In the most recent fiscal year, Xencor reported a revenue of USD 110.49 mn and an EBITDA of USD 190.52 mn. Revenue generation primarily stems from strategic collaborations with larger pharmaceutical firms that utilize its innovative antibody technology in their therapeutic development efforts. These partnerships typically involve licensing agreements, where Xencor receives royalties or milestone payments tied to the progress and success of the partnered drug candidates.Xencor plans to continue expanding its product offerings with new drug candidates under the XmAb brand, focusing on upcoming launches that target various malignancies. The ongoing development of its existing pipeline is essential to this strategy. Furthermore, the company aims to penetrate additional markets, particularly targeting Europe and Asia by the end of 2025. The funds raised from its IPO in December 2013 will support these growth initiatives, particularly in advancing clinical trials and establishing new strategic partnerships.

## Funding rounds

- Series A, Jun 28, 2013, $7.6M — HealthCare Ventures, Oxford Bioscience Partners, Novo Holdings A/S
- Series E, Oct 25, 2007, $15M — Oxford Bioscience Partners, Merlin Nexus, Novo Nordisk A/S
- Series E, Oct 13, 2006, $45M — HealthCare Ventures, MedImmune Ventures, Novo Nordisk A/S, Zen Investments

## Investors

- HealthCare Ventures — Series E, Series A
- MedImmune Ventures (https://capitalatlas.ai/funds/medimmune-ventures) — Series E
- Novo Nordisk A/S — Series E
- Zen Investments — Series E
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series E, Series A
- Merlin Nexus (https://capitalatlas.ai/funds/merlin-nexus) — Series E
- Novo Holdings A/S — Series A